There is a newly approved medication for hepatitis C.
A new weapon is now available in the battle against chronic hepatitis C, and it offers several benefits over its predecessors—most notably, shortened treatment time. The drug, called Mavyret, is a once-daily, ribavirin-free treatment requiring just 8 weeks rather than the standard 12 weeks.
Mavyret showed an overall 98% cure rate across all major genotypes and can also be used to treat patients with genotype 1 infection who were not successfully treated with other direct-acting antiviral treatments previously, according to FDA’s Center for Drug Evaluation and Research. The most common side effects were headache and tiredness.
This new hep C treatment is from Chicago-based pharmaceutical maker AbbVie, which has reportedly priced the pan-genotypic medication at $26,400 for the entire course of treatment. This compares to list prices of nearly $28,000 for AbbVie’s own Viekira Pak and $31,500 for Gilead’s Harvoni.
Read full article: New Drug Approved for all Hep C Strains – Mediware Information Systems
|Read Full Article: New Drug Approved for all Hep C Strains – Mediware Information Systems|